All News
Low Dose IL-2 Therapy in Sjögren’s
There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that lLD-IL-2 was effective and well tolerated in patients with pSS, with evidence of restored immune balance.
https… https://t.co/r0AlTD45gG
Dr. John Cush RheumNow ( View Tweet)
ACR22: Polymyalgia Rheumatica in the Spotlight
One of the enduring legacies of #ACR22 for Dr. Putman ( @EBRheum) will be the emphasis on PMR. Despite being highly inflammatory and relatively common, a remarkable paucity of trials have been run.
https://t.co/4BpvYlKijY https://t.co/fTYYdmcE9X
Links:
Dr. John Cush RheumNow ( View Tweet)
Etoricoxib and Celecoxib may lower CVA risk. Taiwanese study of 10,857 newly Dx RA pts. Coxib use vs non-use compared re: future CVA. Celecoxib pts had reduced CVA (HR 0.67 @200/d; HR 0.22 if <3.5 yrs). Etoricoxib also (HR 0.35; 0.16–0.80) https://t.co/z3RTFt1hPb https://t.co/7rGn41qeu9
Links:
Dr. John Cush RheumNow ( View Tweet)
The Great Debate: To Treat or Not to Treat Pre RA
Dr. Janet Pope ( @Janetbirdope) and Dr. Jonathan Kay ( @RheumKay) discuss the Great Debate, which Dr. Pope participated in, at #ACR22.
https://t.co/s8FQ2l7k6Z https://t.co/zICWqhTfGL
Links:
Dr. John Cush RheumNow ( View Tweet)
Proceedings of the Royal Society of Medicine and Fibromyalgia Action UK Webinar: Fibromyalgia in the 21st century: Redefining care. https://t.co/s02Ue47m6o https://t.co/FZYI7E8D3f
Links:
Dr. John Cush RheumNow ( View Tweet)
JAMA - Update/Review of Hemochromatosis Dx and Rx.
- 5 gene defects in hepcidin. 95% HFE & the C282Y variant
- 90%are asymptomatic
- Suspicion w/ arthralgias, LFTs, hepatomegaly, cardiomyopathy, 1st degr relative
- Untreated, 9% risk of cirrhosis
https://t.co/CVDbXtqOBw https://t.co/R4ed2FNxdh
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 294 SLE pts on HCQ (2005-2021): 37 (13%) developed CHF w/ low EF (HFrEF), arrhythmia or cardiac death. After adjustments, wt-based dosing of HCQ not assoc w/ cardiac events(sHR 0.62; 0.41,0.92) & may decrease risk in non-smokers https://t.co/Qyp2odOfpj https://t.co/Q1qdv0CQ5P
Links:
Dr. John Cush RheumNow ( View Tweet)
Tyk2 Inhibition Effective in SLE
Deucravacitinib, an oral, selective TYK2 inhibitor, has demonstrated efficacy in a phase II trial active systemic lupus erythematosus (SLE) patients.
https://t.co/6pqRZO2VNA https://t.co/iJfhyRs8nw
Links:
Dr. John Cush RheumNow ( View Tweet)
Follow us on LinkedIn too!
https://t.co/iylzzYRVAB https://t.co/7rKQShIzs5
Links:
Dr. John Cush RheumNow ( View Tweet)
New podcast available! Download where ever you get your podcasts and when can--rate, review and subscribe!
Rheum Manpower Needs - More Programs
https://t.co/W0mOCkyJbI https://t.co/USXTAtrE6U
Links:
Dr. John Cush RheumNow ( View Tweet)
The spicy topic of turmeric in RA
Curcumin has increasingly been promoted as a potential RA therapy, but data presented at #ACR22 suggests it is unable to do any better than placebo in replacing conventional rheumatoid arthritis therapies.
https://t.co/C0O0DyXn34 https://t.co/kv3dw476dT
Links:
Dr. John Cush RheumNow ( View Tweet)
Dual target blockade may be better than one in SLE
Inhibition of B-cell Activating Factor (BAFF) has revolutionised the treatment of patients with systemic lupus erythematosus (SLE).
https://t.co/uu6ygb4l8B https://t.co/nLO3oSiEVa
Links:
Dr. John Cush RheumNow ( View Tweet)
JAK inhibitors in rheumatic diseases
Dr. Antoni Chan ( @synovialjoints) discusses abstracts 0510 and 0404 at #ACR22
https://t.co/7SSJITLrRT https://t.co/utjf8vlJof
Links:
Dr. John Cush RheumNow ( View Tweet)
AI Future of Sacroiliitis Assessment
Dr. Rachel Tate ( @uptoTate) speaks with Dr. Fabian Proft about Abstract 0383 at #ACR22 Convergence.
https://t.co/pfeW4iQBLq https://t.co/0lFx6CpWCx
Links:
Dr. John Cush RheumNow ( View Tweet)
Can I stop Methotrexate in RA?
Dr. Pope and Dr. Meng discuss Abstract 0916 at #ACR22.
https://t.co/0hK5kNHlrS https://t.co/AXJija7Yzo
Links:
Dr. John Cush RheumNow ( View Tweet)
Remibrutinib in Sjogren's Syndrome
Dr. Putman reports on abstract 1113 presented at #ACR22 Convergence Abstract 1113: Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study
https://t.co/ymFkNWPaXo https://t.co/0k6vLIu0Ku
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheum Drugs & IDSA Guidelines to Treat COVID-19
https://t.co/39wTAKW83E https://t.co/ir1x66FSQ8
Links:
Dr. John Cush RheumNow ( View Tweet)
RECITAL Trial: RTX vs. CTX in CTD-ILD
A UK study suggests the equivalent outcomes when patients with ILD associated with CTD are treated with either intravenous RTX or CTX, but with fewer adverse events with RTX.
https://t.co/5yaPDaw8pZ https://t.co/kcKLkIv1bK
Links:
Dr. John Cush RheumNow ( View Tweet)
Recent CDC/MMWR report shows Paxlovid x 5days (including those w/ prior COVID or vaccination), had a 51% lower hospitalization rate within 30 days after diagnosis than those not prescribed Paxlovid. Use it irrespective of vaccination status https://t.co/CBc1VBSDFR https://t.co/EC8QGaFrb3
Links:
Dr. John Cush RheumNow ( View Tweet)
Future therapy? Nanoparticles laced with rapamycin to nanoparticle stimulate regulatory T cells to suppress autoimmune disease (tested in a mouse model). https://t.co/JHFh82siff https://t.co/Y8itPXiPho
Links:
Dr. John Cush RheumNow ( View Tweet)
